Cargando…
Structural Basis for the Regulation of PPARγ Activity by Imatinib
Imatinib is an effective anticancer drug for the treatment of leukemia. Interestingly, when an FDA-approved drug library was tested for agents that block peroxisome proliferator-activated receptor γ (PPARγ) phosphorylation at Ser245 to evaluate possibilities of antidiabetic drug repositioning, imati...
Autores principales: | Jang, Jun Young, Kim, Hyun-Jung, Han, Byung Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803859/ https://www.ncbi.nlm.nih.gov/pubmed/31581474 http://dx.doi.org/10.3390/molecules24193562 |
Ejemplares similares
-
Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018) -
Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
por: Jang, Jun Young, et al.
Publicado: (2019) -
Publisher Correction: Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
por: Jang, Jun Young, et al.
Publicado: (2019) -
Differential Effects of Cancer-Associated Mutations Enriched in Helix H3 of PPARγ
por: Jang, Dong Man, et al.
Publicado: (2020) -
Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds
por: Harada, Shusaku, et al.
Publicado: (2015)